MPMary Potasek

Mary Potasek

*This is an algorithmically generated author record based on publicly available information.

Mary Potasek has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Photodynamic therapy and immune response in solid tumours

    by Mary Potasek, Karl Beeson

    Photodynamic therapy can stimulate a person’s own immune system to better recognise – and fight – cancer tumours, say Mary Potasek, PhD and Karl Beeson, PhD of Simphotek and Theresa M Busch, PhD of the Department of Radiation Oncology, University of Pennsylvania

  • Open Access

    Computational Optimization of Irradiance and Fluence for Interstitial Photodynamic Therapy Treatment of Patients with Malignant Central Airway Obstruction

    by Emily Oakley, Evgueni Parilov, Karl Beeson, Mary Potasek, Nathaniel Ivanick, Lawrence Tworek, Alan Hutson, Gal Shafirstein

    There are no effective treatments for patients with extrinsic malignant central airway obstruction (MCAO). In a recent clinical study, we demonstrated that interstitial photodynamic therapy (I-PDT) is a safe and potentially effective treatment for patients with extrinsic MCAO. In previous preclinical studies, we reported that a minimum light irradiance and fluence should be maintained within a significant volume of the target tumor to obtain an effective PDT response. In this paper, we present a computational approach to personalized treatment planning of light delivery in I-PDT that simultaneously optimizes the delivered irradiance and fluence using finite element method (FEM) solvers of either Comsol Multiphysics® or Dosie™ for light propagation. The FEM simulations were validated with light dosimetry measurements in a solid phantom with tissue-like optical properties. The agreement between the treatment plans generated by two FEMs was tested using typical imaging data from four patients with extrinsic MCAO treated with I-PDT. The concordance correlation coefficient (CCC) and its 95% confidence interval (95% CI) were used to test the agreement between the simulation results and measurements, and between the two FEMs treatment plans. Dosie with CCC = 0.994 (95% CI, 0.953–0.996) and Comsol with CCC = 0.999 (95% CI, 0.985–0.999) showed excellent agreement with light measurements in the phantom. The CCC analysis showed very good agreement between Comsol and Dosie treatment plans for irradiance (95% CI, CCC: 0.996–0.999) and fluence (95% CI, CCC: 0.916–0.987) in using patients’ data. In previous preclinical work, we demonstrated that effective I-PDT is associated with a computed light dose of ≥45 J/cm2 when the irradiance is ≥8.6 mW/cm2 (i.e., the effective rate-based light dose). In this paper, we show how to use Comsol and Dosie packages to optimize rate-based light dose, and we present Dosie’s newly developed domination sub-maps method to improve the planning of the delivery of the effective rate-based light dose. We conclude that image-based treatment planning using Comsol or Dosie FEM-solvers is a valid approach to guide the light dosimetry in I-PDT of patients with MCAO.


  • Open Access

    Photodynamic Therapy: Killing cancer gently with visible light

    by Mary Potasek, Karl Beeson, Evgueni Parilov

    Photodynamic therapy, using visible light with lower energy, causes fewer side effects when treating cancer, find Simphotek, Inc

  • Open Access

    Simphotek: Shedding Light on New Cancer Treatments

    by Mary Potasek

    The use of radiation therapy to treat cancer has improved the long-term outcome of thousands of patients but is associated with serious side effects. Photodynamic therapy (PDT), a targeted light-based technique, has been approved as an effective treatment for some forms of cancer with fewer side effects than radiotherapy. However, the effectiveness of this technique depends on fine-tuning its application to the patient. Simphotek, a US-based company founded by world leaders in biophysics and computer modelling, together with its collaborative partners at Roswell Park Comprehensive Cancer Center and the Hospital of the University of Pennsylvania, is focused on expanding novel technologies of PDT as a cancer treatment for solid tumours.


  • Open Access

    Interstitial Photodynamic Therapy—A Focused Review

    by Gal Shafirstein, David Bellnier, Emily Oakley, Sasheen Hamilton, Mary Potasek, Karl Beeson, Evgueni Parilov

    Multiple clinical studies have shown that interstitial photodynamic therapy (I-PDT) is a promising modality in the treatment of locally-advanced cancerous tumors. However, the utilization of I-PDT has been limited to several centers. The objective of this focused review is to highlight the different approaches employed to administer I-PDT with photosensitizers that are either approved or in clinical studies for the treatment of prostate cancer, pancreatic cancer, head and neck cancer, and brain cancer. Our review suggests that I-PDT is a promising treatment in patients with large-volume or thick tumors. Image-based treatment planning and real-time dosimetry are required to optimize and further advance the utilization of I-PDT. In addition, pre- and post-imaging using computed tomography (CT) with contrast may be utilized to assess the response.